LAF 237

Known as: LAF-237, LAF237 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2016
012320042016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2013
2013
The long term side effects of any newly introduced drug is a subject of intense research, and often raging controversies. One… (More)
  • figure 1
  • figure 2
  • table 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Dipeptidyl peptidase (DPP) IV inhibitors are probably beneficial for preventing diabetic complication and modulating glucagon… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • figure 3
Is this relevant?
2012
2012
AIM To investigate the combination effects and mechanisms of valsartan (angiotensin II type 1 receptor blocker) and LAF237 (DPP… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2012
2012
Three-dimensional pharmacophore hypothesis was established based on a set of known DPP-IV inhibitor using PharmaGist software… (More)
Is this relevant?
2011
2011
The present study addressed the effect of the dipeptidyl peptidase-4 (DPP-4) inhibitor vildagliptin ((1-[[(3-hydroxy-1-adamantyl… (More)
  • figure 1
  • table 1
  • table 2
Is this relevant?
2011
2011
Fibroblast activation protein-α (FAP) is a cell surface, serine protease of the post-prolyl peptidase family that is expressed in… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2008
2008
LAF237 [(S)-1-[(3-hydroxy-1-adamantyl)ammo]acetyl-2-cyanopyrrolidine] is an inhibitor of dipeptidyl peptidase IV that delays the… (More)
Is this relevant?
2007
2007
Thiazolidinediones (TZDs) are currently the most efficacious class of oral antidiabetics. However, they carry the burden of… (More)
Is this relevant?
Highly Cited
2005
Highly Cited
2005
OBJECTIVE A novel treatment option for diabetic patients is the enhancement of incretin hormone activity by inhibition of the… (More)
Is this relevant?
Highly Cited
2004
Highly Cited
2004
OBJECTIVE To assess the 12- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 versus placebo in patients with… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
Is this relevant?